title: Comparison of IgM-MGUS and IgG-MGUS polyneuropathy.
abstract: OBJECTIVE
  To compare the clinical and electrodiagnostic features and response to treatment in patients with IgM-MGUS and IgG-MGUS associated polyneuropathy.
  
  
  METHODS
  Retrospective review of 34 consecutive patients with MGUS associated neuropathy evaluated over 5 years.
  
  
  RESULTS
  There were 19 patients with IgM-MGUS and 15 with IgG-MGUS. There were no differences in age, duration of symptoms, or distribution of motor and sensory symptoms or signs. IgM-MGUS patients had prolonged distal latencies of the median and ulnar motor potentials, greater slowing of the peroneal nerve conduction velocity and more often absent ulnar sensory potentials. Half of the patients in both groups improved following immunotherapy.
  
  
  CONCLUSIONS
  IgM-MGUS patients had more severe demyelination on the nerve conduction studies, but there were no clinical features that differentiated the 2 groups. IgM and IgG-MGUS patients improved with plasma exchange and other immune therapies. Anti-MAG antibodies failed to distinguish a subgroup of patients with IgM-MGUS neuropathy.
authors.affiliation: Neurology Service, St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA.
authors.forename: D
authors.initials: D
authors.lastname: Simovic
authors.forename: K C
authors.initials: KC
authors.lastname: Gorson
authors.forename: A H
authors.initials: AH
authors.lastname: Ropper
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D001323:Autoantibodies / Q000097:blood; D016009:Chi-Square Distribution; D003711:Demyelinating Diseases / Q000150:complications / Q000276:immunology / Q000628:therapy; D004576:Electromyography; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D007075:Immunoglobulin M / Q000097:blood*; D007167:Immunotherapy / Q000379:methods; D008297:Male; D008875:Middle Aged; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000150:complications* / Q000276:immunology / Q000628:therapy; D009069:Movement Disorders / Q000209:etiology; D018992:Myelin-Associated Glycoprotein / Q000276:immunology; D009431:Neural Conduction; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000276:immunology* / Q000628:therapy; D012189:Retrospective Studies; D012678:Sensation Disorders / Q000209:etiology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D018992:Myelin-Associated Glycoprotein